ALLMedicine™ Anemia Center
Research & Reviews 21,146 results
https://doi.org/10.1177/23259582221109567
Journal of the International Association of Providers of ... Yancheva N, Strashimirov D et. al.
Jul 2nd, 2022 - Non-Langerhans cell histiocytosis is a rare disease which seldom affects adults. We report a case of a 32-year-old Bulgarian woman living with HIV. She developed severe anemia, extreme splenomegaly, requiring splenectomy and vertebral tumor format...
https://clinicaltrials.gov/ct2/show/NCT03520647
Jul 1st, 2022 - Severe aplastic anemia (SAA),myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) are life-threatening bone marrow disorders. For SAA patients, long term survival can be achieved with immunosuppressive treatment. However, ...
https://clinicaltrials.gov/ct2/show/NCT01906489
Jul 1st, 2022 - The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.
https://clinicaltrials.gov/ct2/show/NCT02692872
Jul 1st, 2022 - Many of the complications of sickle cell disease, such as stroke, kidney damage, skin ulceration,pulmonary hypertension, and cardiac hypertrophy are prevented, delayed or reduced by inheritance of one of more deletions of the alpha globin genes. O...
https://clinicaltrials.gov/ct2/show/NCT04436367
Jul 1st, 2022 - Severe aplastic anemia (SAA) is a form of bone marrow failure in most cases is the result of a cytotoxic T cell attack on the marrow stem cell. It is effectively treated in most patients with either immunosuppressive treatment (IST) or allogeneic ...
Guidelines 26 results
https://doi.org/10.1016/j.kint.2021.03.020
Kidney International; Babitt JL, Eisenga MF et. al.
Apr 12th, 2021 - In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis,...
https://doi.org/10.1053/j.gastro.2020.08.036
Gastroenterology Ko CW, Siddique SM et. al.
Aug 31st, 2020 - Spotlight: Gastrointestinal Evaluation of Iron Deficiency Anemia.|2020|Ko CW,Siddique SM,Patel A,Harris A,Altayar O,|blood,diagnosis,etiology,standards,standards,standards,diagnostic imaging,metabolism,pathology,standards,blood,complications,diagn...
https://doi.org/10.1053/j.gastro.2020.08.043
Gastroenterology
Aug 31st, 2020 - GI Evaluation of Iron Deficiency Anemia: Clinical Decision Support Tool.|2020| ,|blood,diagnosis,etiology,standards,methods,standards,standards,diagnostic imaging,metabolism,pathology,standards,blood,complications,diagnosis,pathology,analysis,diag...
https://doi.org/10.1053/j.gastro.2020.06.046
Gastroenterology Ko CW, Siddique SM et. al.
Aug 19th, 2020 - AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia.|2020|Ko CW,Siddique SM,Patel A,Harris A,Sultan S,|blood,diagnosis,epidemiology,etiology,standards,standards,diagnostic imaging,metabolism,pathology,stan...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the Am... Bohlius J, Bohlke K et. al.
Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomiz...
Drugs 823 results see all →
Clinicaltrials.gov 2,755 results
https://clinicaltrials.gov/ct2/show/NCT01906489
Jul 1st, 2022 - The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.
https://clinicaltrials.gov/ct2/show/NCT04436367
Jul 1st, 2022 - Severe aplastic anemia (SAA) is a form of bone marrow failure in most cases is the result of a cytotoxic T cell attack on the marrow stem cell. It is effectively treated in most patients with either immunosuppressive treatment (IST) or allogeneic ...
https://clinicaltrials.gov/ct2/show/NCT04436380
Jul 1st, 2022 - Severe aplastic anemia (SAA) is a form of bone marrow failure and in most cases is the result of a cytotoxic T cell attack on the marrow stem cell. It is effectively treated in most patients with either immunosuppressive treatment (IST) or upfront...
https://clinicaltrials.gov/ct2/show/NCT02692872
Jul 1st, 2022 - Many of the complications of sickle cell disease, such as stroke, kidney damage, skin ulceration,pulmonary hypertension, and cardiac hypertrophy are prevented, delayed or reduced by inheritance of one of more deletions of the alpha globin genes. O...
https://clinicaltrials.gov/ct2/show/NCT03520647
Jul 1st, 2022 - Severe aplastic anemia (SAA),myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) are life-threatening bone marrow disorders. For SAA patients, long term survival can be achieved with immunosuppressive treatment. However, ...
News 3,526 results
https://www.mdedge.com/fedprac/avaho/article/255829/multiple-myeloma/simultaneous-cases-carfilzomib-induced-thrombotic
Nathaniel J. Myall, MD, Samantha X. Wang, MD et. al.
Jun 28th, 2022 - As a class of drugs, proteasome inhibitors are known to rarely cause drug-induced thrombotic microangiopathy (DITMA). In particular, carfilzomib is a second-generation, irreversible proteasome inhibitor approved for the treatment of relapsed, refr.
https://www.mdedge.com/hematology-oncology/article/255632/gastrointestinal-cancer/advanced-gastric-cancer-ramucirumab
Jun 22nd, 2022 - Key clinical point: Ramucirumab in combination with irinotecan fails to improve the progression-free survival (PFS) rate at 6 months in patients with previously treated advanced gastric cancer. Major finding: The 6-month PFS rate was 26.
https://www.medscape.com/viewarticle/975651
Jun 15th, 2022 - The investigational drug momelotinib has shown benefits in myelofibrosis in a new phase 3 trial, which could now lead to a Food and Drug Administration approval. This drug had previously shown mixed results in a phase 3 trial funded by Gilead, whi...
https://www.mdedge.com/hematology-oncology/article/255402/cml/momelotinib-hits-mark-deadly-bone-marrow-cancer
Heidi Splete
Jun 13th, 2022 - The investigational drug momelotinib has shown benefits in myelofibrosis in a new phase 3 trial, which could now lead to a Food and Drug Administration approval. This drug had previously shown mixed results in a phase 3 trial funded by Gilead, whi.
https://www.mdedge.com/psychiatry/article/255053/schizophrenia-other-psychotic-disorders/should-clozapine-be-discontinued
Tyler C. Wright, MD, MPH, Stephanie H. Cho, MD, MS
Jun 1st, 2022 - CASE Schizophrenia, leukemia, and chemotherapy Mr. A, age 30, has schizophrenia but has been stable on clozapine 600 mg/d.